2 Best Buys of the Nasdaq Right Now

92
15
Favorite

2 Best Buys of the Nasdaq Right Now

Motley Fool2021-07-28

Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（15）

Uasbau
·2021-07-30
Interesting
Reply
Like
Report
SinyinC
·2021-07-29
[Thinking]
Reply
1
Report
Seimin
·2021-07-29
Really?!
Reply
1
Report
诗迷
·2021-07-29
Like and comment
Reply
Like
Report
NgKenny
·2021-07-29
Nice
Reply
Like
Report
NgKenny
·2021-07-29
Nice
Reply
Like
Report
stormlee
·2021-07-29
Comment & like pls
Reply
Like
Report
Venture Tige
·2021-07-29
Amazon is amazing
Reply
1
Report
littlekitten
·2021-07-29
Really?
Reply
2
Report
Fold Replies
- stormlee:
  Comment & like pls
  2021-07-29
  Reply
  Report
k2000
·2021-07-29
Nice
Reply
Like
Report
Fold Replies
- Benstonk:
  Ok
  2021-07-29
  Reply
  Report
BelleQ
·2021-07-29
Nice
Reply
1
Report
Fold Replies
- vic78:
  ?
  2021-07-29
  Reply
  Report
- Zack克明冲:
  $AMC Entertainment(AMC)$ all the way!
  2021-07-29
  Reply
  Report
PoloMimi
·2021-07-28
?
Reply
2
Report
SHAJ
·2021-07-28
Inari. Promising
Reply
3
Report
sengfuh
·2021-07-28
Cool
Reply
3
Report
GWS
·2021-07-28
[Smile]
Reply
3
Report
Fold Replies
- sengfuh:
  Haha
  2021-07-28
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2154236859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-28 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2154236859","market":"us","top_or_hot":-1,"title":"2 Best Buys of the Nasdaq Right Now","media":"Motley Fool","content":"<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QLD","symbol_name":"纳指两倍做多ETF","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","article_id":"2154236859","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","pubTimestamp":1627483328,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The overall market might be expensive, but these stocks aren't.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","TQQQ":"纳指三倍做多ETF","NDAQ":"纳斯达克OMX交易所","BBY":"百思买","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","QQQ":"纳指100ETF","SQQQ":"纳指三倍做空ETF"},"translate_title":"现在买2件纳斯达克最好的东西","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.9,"BBY":0.9,"BOTB.UK":0.9,"MNQmain":0.9,"NQmain":0.9,"NDAQ":0.9,"PSQ":0.9,"QID":0.9,"QLD":0.9,"QQQ":0.9,"SQQQ":0.9,"TQQQ":0.9},"content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":808516545,"gmtCreate":1627601530587,"gmtModify":1703493016352,"author":{"id":"3581724772671504","authorId":"3581724772671504","name":"Uasbau","avatar":"https://static.tigerbbs.com/67cdf409f2239595269918513a5faac9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581724772671504","authorIdStr":"3581724772671504"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808516545","repostId":2154236859,"repostType":2,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801799122,"gmtCreate":1627532545966,"gmtModify":1703491837501,"author":{"id":"4090067472793680","authorId":"4090067472793680","name":"SinyinC","avatar":"https://static.tigerbbs.com/25e6228aa6e4deba83436507ecd7a706","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4090067472793680","authorIdStr":"4090067472793680"},"htmlText":"[Thinking]&nbsp;","listText":"[Thinking]&nbsp;","text":"[Thinking]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801799122","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801671820,"gmtCreate":1627516789060,"gmtModify":1703491390958,"author":{"id":"3565837831314409","authorId":"3565837831314409","name":"Seimin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3565837831314409","authorIdStr":"3565837831314409"},"htmlText":"Really?!","listText":"Really?!","text":"Really?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801671820","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801667571,"gmtCreate":1627515516993,"gmtModify":1703491343318,"author":{"id":"3586570953514754","authorId":"3586570953514754","name":"诗迷","avatar":"https://static.tigerbbs.com/ede7919964a05a6754d4489382883c39","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3586570953514754","authorIdStr":"3586570953514754"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801667571","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801684764,"gmtCreate":1627515118558,"gmtModify":1703491327557,"author":{"id":"3582778356971864","authorId":"3582778356971864","name":"NgKenny","avatar":"https://static.tigerbbs.com/4fdae3e0bdca8d3a33e7f9d619f0dc88","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3582778356971864","authorIdStr":"3582778356971864"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801684764","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801688189,"gmtCreate":1627514857641,"gmtModify":1703491320232,"author":{"id":"3582778356971864","authorId":"3582778356971864","name":"NgKenny","avatar":"https://static.tigerbbs.com/4fdae3e0bdca8d3a33e7f9d619f0dc88","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3582778356971864","authorIdStr":"3582778356971864"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801688189","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801635323,"gmtCreate":1627514251762,"gmtModify":1703491295576,"author":{"id":"3571959390768435","authorId":"3571959390768435","name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571959390768435","authorIdStr":"3571959390768435"},"htmlText":"Comment &amp; like pls","listText":"Comment &amp; like pls","text":"Comment & like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801635323","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801844413,"gmtCreate":1627512500732,"gmtModify":1703491238618,"author":{"id":"4090445363917420","authorId":"4090445363917420","name":"Venture Tige","avatar":"https://static.tigerbbs.com/a18283fb7f4deb183ffc1d651a821298","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4090445363917420","authorIdStr":"4090445363917420"},"htmlText":"Amazon is amazing&nbsp;","listText":"Amazon is amazing&nbsp;","text":"Amazon is amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801844413","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801846219,"gmtCreate":1627512289631,"gmtModify":1703491234567,"author":{"id":"3584860762907200","authorId":"3584860762907200","name":"littlekitten","avatar":"https://static.tigerbbs.com/ccd59ff6c96999c839e3b5709cfb00ef","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3584860762907200","authorIdStr":"3584860762907200"},"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/801846219","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5362329,"gmtCreate":1627514261585,"gmtModify":1663231638649,"authorId":3571959390768435,"author":{"id":3571959390768435,"idStr":"3571959390768435","authorId":3571959390768435,"name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":801846219,"type":1,"supId":0,"prevId":0,"content":"Comment &amp; like pls","text":"Comment &amp; like pls","html":"Comment &amp; like pls"}],"langContent":"EN"},{"id":801821512,"gmtCreate":1627510617936,"gmtModify":1703491203484,"author":{"id":"4087443573108990","authorId":"4087443573108990","name":"k2000","avatar":"https://static.tigerbbs.com/24bf802bad93726dcd0c1e73228cbae2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087443573108990","authorIdStr":"4087443573108990"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/801821512","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5361899,"gmtCreate":1627512083270,"gmtModify":1663231638847,"authorId":3574851080358491,"author":{"id":3574851080358491,"idStr":"3574851080358491","authorId":3574851080358491,"name":"Benstonk","avatar":"https://static.tigerbbs.com/c8a964cfa9223e4704989c9a4b9b772e","vip":1,"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":801821512,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":801803368,"gmtCreate":1627493954154,"gmtModify":1703491122604,"author":{"id":"4088569025235550","authorId":"4088569025235550","name":"BelleQ","avatar":"https://static.tigerbbs.com/a71452c56af93175273899556672ba3c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088569025235550","authorIdStr":"4088569025235550"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/801803368","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5361548,"gmtCreate":1627508812181,"gmtModify":1663231637741,"authorId":3584874174562489,"author":{"id":3584874174562489,"idStr":"3584874174562489","authorId":3584874174562489,"name":"vic78","avatar":"https://static.tigerbbs.com/d4dc3bd30cec435b0345175f72eeb4dc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":801803368,"type":1,"supId":5361470,"prevId":0,"content":"?","text":"?","html":"?"},{"id":5361470,"gmtCreate":1627507632805,"gmtModify":1663231637649,"authorId":3574222119045289,"author":{"id":3574222119045289,"idStr":"3574222119045289","authorId":3574222119045289,"name":"Zack克明冲","avatar":"https://static.tigerbbs.com/87d4276781b63267606929e671232344","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":801803368,"type":1,"supId":0,"prevId":0,"content":"<a href=\"https://laohu8.com/S/AMC\"> $AMC Entertainment(AMC)$ </a> all the way!","text":"<a href=\"https://laohu8.com/S/AMC\"> $AMC Entertainment(AMC)$ </a> all the way!","html":"<a href=\"https://laohu8.com/S/AMC\"> $AMC Entertainment(AMC)$ </a> all the way!"}],"langContent":"EN"},{"id":801375331,"gmtCreate":1627485360023,"gmtModify":1703490973838,"author":{"id":"4087893003758890","authorId":"4087893003758890","name":"PoloMimi","avatar":"https://static.tigerbbs.com/e2de4a943e56d4c7d0e12623268a0290","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087893003758890","authorIdStr":"4087893003758890"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801375331","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801372498,"gmtCreate":1627485335714,"gmtModify":1703490973014,"author":{"id":"3573708491598785","authorId":"3573708491598785","name":"SHAJ","avatar":"https://static.tigerbbs.com/bd7cb9c446f2a757b685fbfa4ef1dbd9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573708491598785","authorIdStr":"3573708491598785"},"htmlText":"Inari. Promising","listText":"Inari. Promising","text":"Inari. Promising","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801372498","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801354153,"gmtCreate":1627484394672,"gmtModify":1703490945536,"author":{"id":"3557632577472341","authorId":"3557632577472341","name":"sengfuh","avatar":"https://static.tigerbbs.com/221eceb3fd757b12b2f77f2d96659412","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3557632577472341","authorIdStr":"3557632577472341"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801354153","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":801350222,"gmtCreate":1627483975466,"gmtModify":1703490934282,"author":{"id":"4087469716432460","authorId":"4087469716432460","name":"GWS","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087469716432460","authorIdStr":"4087469716432460"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/801350222","repostId":2154236859,"repostType":4,"repost":{"id":"2154236859","pubTimestamp":1627483328,"share":"https://ttm.financial/m/news/2154236859?lang=&edition=fundamental","pubTime":"2021-07-28 22:42","market":"us","language":"en","title":"2 Best Buys of the Nasdaq Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2154236859","media":"Motley Fool","summary":"The overall market might be expensive, but these stocks aren't.","content":"<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.</p>\n<p>It's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- <b>Amazon.com</b> (NASDAQ:AMZN) and <b>Inari</b> <b>Medical</b> (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635393%2Fgettyimages-1321334275.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Amazon</h2>\n<p>Amazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.</p>\n<p>Amazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c45c30fb2b5329f8a0a1aa920adafaab\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>AMZN PS Ratio data by YCharts</span></p>\n<p>Long-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.</p>\n<h2>2. Inari Medical</h2>\n<p>Inari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve <a href=\"https://laohu8.com/S/AONE.U\">one</a> primary goal: remove large clots from veins without using dangerous blood-thinning drugs.</p>\n<p>Its two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.</p>\n<p>Thanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9e90399e5b8b528ae039d556bf1853d1\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>NARI PS Ratio data by YCharts</span></p>\n<p>It is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.</p>\n<p>For investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Buys of the Nasdaq Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Buys of the Nasdaq Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","BBY":"百思买","NDAQ":"纳斯达克OMX交易所","QID":"纳指两倍做空ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF"},"source_url":"https://www.fool.com/investing/2021/07/28/2-best-buys-of-the-nasdaq-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154236859","content_text":"Stocks can make fools of even the smartest people. Many have been calling the current market a bubble for years. The price-to-sales (P/S) ratio of the Nasdaq Composite reached 2.6 in 2007 before crashing. It surpassed that by the end of 2015, leading many to point to another imminent collapse. Since then, the Nasdaq Composite is up 190%. That P/S ratio is now double what it was in 2007. There is a reason timing the market is considered nearly impossible.\nIt's why Warren Buffett has said it's better to buy a great company at a fair price than a fair company at a great price. Over time, the advantages of those great companies will keep compounding. As another great investor puts it, \"winners keep on winning.\" That's why now might be a good time to add two great Nasdaq stocks -- Amazon.com (NASDAQ:AMZN) and Inari Medical (NASDAQ:NARI) -- to your portfolio despite the sky-high valuations of the overall index.\nImage source: Getty Images.\n1. Amazon\nAmazon needs no introduction. It virtually defined online commerce and cloud computing over the past two decades. Despite already being such a window into the American economy, it has become even more important during the pandemic. That's evident by the ridiculous numbers the nearly $2 trillion company has been putting up. Revenue in 2020 was up 38% year-over-year. The momentum carried over into the first quarter, when the company posted 44% sales growth.\nAmazon's trailing-12-month revenue is $419 billion. After it reports earnings this week, that number should jump to at least $446 billion. It's almost double what it was in 2018. At the current stock price, that would give the company a P/S ratio of 4.0. That's inline with its average of the past three years.\nAMZN PS Ratio data by YCharts\nLong-term outperformance is about buying great companies at a reasonable price. Everyone would love to have another chance to add shares at the pandemic lows, but it could be years before investors get another opportunity like that. Even then, the share price could be much higher than it is now. That's why it's time to take advantage while the shares are reasonably priced. Once Amazon reports earnings Thursday, its stock may once again command a premium.\n2. Inari Medical\nInari's $4 billion market cap is tiny compared to Amazon. Unlike the everything store, it has helped clinicians achieve one primary goal: remove large clots from veins without using dangerous blood-thinning drugs.\nIts two disposable systems -- ClotTreiver and FlowTreiver -- have led to sales growing twentyfold from 2018 to 2020. Revenue grew 113% year-over-year in the most recent quarter. Despite the torrid growth, the stock has been struggling recently. It's down about 9% since it reported those first quarter earnings in May compared to a 9% gain for the Nasdaq overall.\nThanks to the combination of huge revenue growth and the drop in the stock price, the PS ratio is at 22. That's the lowest level investors have been able to buy shares since the company went public in May 2020. When Inari delivers its second quarter report, that ratio should drop to at least 20.\nNARI PS Ratio data by YCharts\nIt is still an elevated ratio for a company that isn't selling software, but its 90% gross margins and greater than 100% sales growth make it an unusual bargain relative to its 14 months as a public company.\nFor investors scanning the horizon for relative value in an expensive market, Inari Medical offers hypergrowth and profitability at a relative discount. The stock is already my second largest holding. But for those who don't yet have a position, now could be the perfect time to add one of the best buys in the Nasdaq.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5360002,"gmtCreate":1627484406952,"gmtModify":1663231630948,"authorId":3557632577472341,"author":{"id":3557632577472341,"idStr":"3557632577472341","authorId":3557632577472341,"name":"sengfuh","avatar":"https://static.tigerbbs.com/221eceb3fd757b12b2f77f2d96659412","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":801350222,"type":1,"supId":0,"prevId":0,"content":"Haha","text":"Haha","html":"Haha"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":92,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}